{"entity":{"id":"nct06959082","kind":"trial","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","aka":[],"tldr":"A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by VSPharmTech Co.,Ltd., now recruiting.","summary":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer is a phase 2 interventional study registered as NCT06959082 by VSPharmTech Co.,Ltd., with 30 participants planned, started 2025-06-11 and due to reach its primary completion in 2027-12. Interventions recorded: VS-101, Cisplatin and Radiation.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06959082","url":"https://clinicaltrials.gov/study/NCT06959082"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06959082","phase":"2","setting":"A Multi-center, Randomized, Open-label, Parallel-group, Phase 2 Study to Evaluate the Efficacy and Safety of VS-101 in Combination With Chemoradiotherapy (CRT) in Patients With Head and Neck Cancer","sponsor":"VSPharmTech Co.,Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct06959082/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}]}}